Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Inclusion Criteria: * Patients must have histologically confirmed malignancy that is metastatic or unresectable * Patient must have histopathologic confirmation of advanced solid tumor with NF1 mutation, NF1 mutant MPNST, KEAP1/NRF2 mutant and STK11/LKB1 mutant tumors (molecular profiling performed in any Clinical Laboratory Improvement Act \[CLIA\] certified lab \[including tumor and circulating cell-free (cf)DNA\], e.g. Caris, FoundationOne, FoundationAct, Oncomine, Guardant etc.) * NOTE: For all cohorts annotation for actionability will be performed by the PRECISION ONCOLOGY DECISION SUPPORT (PODS) TEAM SHEIKH KHALIFA BIN ZAYED AL NAHYAN INSTITUTE FOR PERSONALIZED CANCER THERAPY (IPCT) THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 6565 MD ANDERSON BLVD, HOUSTON, TX 77030 * Patient must have no standard therapies available * Patient must be aged greater than 18 years old for all cohorts * Patients for NF1 mutant MPNST and NF1 mutant non-MPNST cohorts must be \>= 40 kg * Patient must be at least 4 weeks since any prior surgery or radiotherapy * Females of childbearing potential must have a negative serum pregnancy test (=\< 14 days) prior to start of trial treatment * Response Evaluation Criteria in Solid Tumors (RECIST) measurable disease and biopsiable targetable lesion * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axi…